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ABSTRACT
The COVID-19 pandemic has been a disruptive event for cancer patients, especially those with
haematological malignancies (HM). They may experience a more severe clinical course due to
impaired immune responses. This multi-center retrospective UK audit identified cancer patients
who had SARS-CoV-2 infection between 1 March and 10 June 2020 and collected data pertain-
ing to cancer history, COVID-19 presentation and outcomes. In total, 179 patients were identi-
fied with a median age of 72 (IQR 61, 81) and follow-up of 44days (IQR 42, 45). Forty-one
percent were female and the overall mortality was 37%. Twenty-nine percent had HM and of
these, those treated with chemotherapy in the preceding 28days to COVID-19 diagnosis had
worse outcome compared with solid malignancy (SM): 62% versus 19% died [HR 8.33 (95% CI,
2.56–25), p< 0.001]. Definite or probable nosocomial SARS-CoV-2 transmission accounted for
16% of cases and was associated with increased risk of death (HR 2.47, 95% CI 1.43–4.29,
p¼ 0.001). Patients with haematological malignancies and those who acquire nosocomial trans-
mission are at increased risk of death. Therefore, there is an urgent need to reassess shielding
advice, reinforce stringent infection control, and ensure regular patient and staff testing to pre-
vent nosocomial transmission.
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In December 2019, severe acute respiratory syndrome cor-
onavirus 2 (SARS-CoV-2), which causes coronavirus disease
(COVID-19), emerged in Wuhan, China [1,2]. SARS-CoV-2
has since gone on to cause a global pandemic, which has
caused significant disruption to routine healthcare.
Individuals with cancer are more prone to respiratory
viruses as a result of immunosuppression from either the
underlying disease or therapy. For example, the mortality
rate from influenza [3,4], and even rhinovirus, can be
increased in certain populations [5]. The mortality rate in
cancer patients with COVID-19 is higher than the back-
ground population and patients with no history of can-
cer, when adjusted for other potentially explanatory
variables, such as age and comorbidities [6].
As a result, patients receiving chemotherapy for
malignancy have been classified as high risk in the UK
[7]. However, it is not clear whether the risk is the
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same across all cancer types. Patients with haemato-
logical malignancy, who are usually more immunosup-
pressed than those with solid organ tumors, may have
a higher risk of death from COVID-19. To examine the
effect of COVID-19 on our patients, we conducted a
multicentre retrospective audit. We examined the dif-
ference in outcomes between solid organ and haem-
atological malignancy and the outcome effect of
recent chemotherapy treatment, to inform manage-
ment of cancer patients.
Methods
Study design and participants
This multicentre audit collected data from cancer
patients who were hospitalized with COVID-19
between 1 March 2020 and 10 June 2020 across six
NHS hospitals in England: The Clatterbridge Cancer
Center, Liverpool University Hospitals, Arrowe Park
Hospital, Royal Albert Edward Infirmary, The Christie
and North Middlesex University Hospital. The mortality
in patients with cancer in a large prospective cohort
UK study (ISARIC WHO CCP-UK) was 44% [6,8], with
which we compared our outcomes. To allow compari-
son with the CCP-UK patient cohort, we only recorded
hospitalized patients with COVID-19. Each centre’s
governance team approved the audit. All patients
included were SARS-CoV-2 positive as determined by
each center’s approved PCR testing protocol – irre-
spective of signs or symptoms [9].
Data collection
Data were collected locally from patients’ medical
records using a standard proforma. We collected age,
sex, ethnicity, postcode, cancer history, comorbidities
(defined in Supplementary Methods), presenting
symptoms, results of radiological examinations
(Supplementary Methods), and laboratory results.
Details of the COVID-19 episode, duration of hospital
admission, and any related complications were also
collected. Patients were monitored until discharge,
death, or last available follow-up. The final date of
data collection was 17 June 2020.
Cancer-specific information
Cancer-related data included date of diagnosis, type of
primary cancer, treatment history including nature
(surgery, radiotherapy, chemotherapy, endocrine ther-
apy, or immunotherapy), and intent of treatment
(induce remission, curative, adjuvant, neoadjuvant,
radical, watch and wait, non-curative and palliative) as
well as the date of last treatment. Where treatments
were halted due to COVID-19 and the patient sur-
vived, information relating to whether treatment was
restarted was sought. Definitions used have been sum-
marized in Supplementary Methods.
Nosocomial and community-acquired transmission
‘Definite’ nosocomial transmission was a COVID-19
diagnosis made >14 days after admission; ‘probable’ if
diagnosis was 8–14 days after admission;
‘indeterminate’ if diagnosis was 3–7 days after admis-
sion and ‘community-acquired’ if diagnosis was con-
firmed <3 days since admission [10].
Severity of illness and mortality rate
Definitions of severity of illness were adapted from
other publications [9,11–14]. Disease was ‘mild’ if
patients did not require oxygen throughout admission;
‘moderate,’ if the oxygen saturations were recorded to
be <93% or they required at least 0.35 FiO2 therapy;
and ‘severe,’ if they required intensive care unit (ICU)
admission or died. Mortality rate was the proportion
of patients who died at any point before final
data extraction.
Statistical analyses
Continuous data are presented as median (IQR) and
categorical data are reported as frequencies of counts
and associated percentages. Differences in the distri-
bution of data between haematological and solid
malignancy types were assessed using Wilcox test/t-
test for continuous data and Fisher’s/Chi-square test
for categorical data. The main outcomes were the
mortality rate, which was compared to ISARIC WHO
CCP-UK and time-to-death from positive SARS-CoV-2




In total, 179 SARS-CoV-2 positive cancer patients were
identified (Table 1). The median age of all cancer
patients was 72 (IQR 61, 81), 59% (105 of 179) were
male and 82% (75 of 92) were White. The median dur-
ation of follow-up was 44 days (IQR 42, 45). Twenty-
nine percent (52 of 179 patients) had haematological
malignancy (HM) and 71% (127 of 179) had solid
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malignancy (SM), with malignancy subtypes summar-
ized in Table 2. Nineteen percent (30 of 161) had
received a cancer diagnosis within 3months of COVID-
19. Forty-eight percent (86 of 179) had received anti-
cancer treatment within 4weeks of COVID-19 [58% (30
of 52) for HM and 44% (56 of 127) for SM].
There were no significant differences in comorbidity
between groups. HM patients came from more
deprived areas, with an index of multiple deprivation
decile score of 4 (IQR 1.75, 8), compared with a score
in SM patients of 3 (IQR 1, 5), p¼ 0.039.
Nosocomial infection
The majority of COVID-19 cases, 81% (145 of 179),
were community acquired. Eight percent (15 of 179)
of infections were ‘definite’ nosocomial. ‘Probable’ and
‘indeterminate’ cases accounted for 7% (13 of 179)
and 3% (6 of 179), respectively (Figure 1(A)). Together,
probable or definite nosocomial infection comprised
16% of cases (29 vs 71% in HM and SM). The mortality
of community-acquired COVID-19 was 32% (36 of
145), very similar to that in the indeterminate group
of 33% (2 of 6). However, of those with probable
nosocomial infection, 69% (9 of 13) died and 60% (9
of 15) with definite nosocomial infection died. In
patients with probable or definite nosocomial infec-
tion, the mortality rate was 75% in HM and 60%
in SM.
Presenting symptoms of COVID-19
Fever was the commonest presenting symptom (60%,
107 of 179), followed by dry cough (55%, 98 of 179)
and shortness of breath (47%, 84 of 179). Respiratory
symptoms were the most common set of presenting
symptoms (75%, 34 of 179) (Supplementary Figure 1).
This was followed by systemic symptoms (71%, 127 of
179) and gastrointestinal (GI) symptoms (21%, 38 of
179). Eleven percent (19 of 179) of patients exhibited
all sets of symptoms. In all patients who had GI and
respiratory symptoms, systemic symptoms were
also present.
Anticancer treatment
Systemic anticancer treatment was administered to
58% (30 of 52) of HM patients and 39% (49 of 127) of
SM patients within 4weeks preceding the COVID-19
episode. Within 4weeks to 12months preceding the
COVID-19 episode, 14% (18 of 127) of HM patients
and 4% (2 of 52) of SM patients received prior treat-
ment, and 9% (12 of 127) vs 11% (6 of 52) received
prior therapy more than 12months of COVID-19 epi-
sode in the HM and SM groups, respectively. None of
the HM patients underwent prior radiotherapy or sur-
gery with 4weeks of COVID-19 compared to 7% (9 of
127) of SM patients. All patients receiving anticancer
therapy at the time of COVID-19 had their treatment
stopped. Of these patients, 27% (8 of 30) and 30% (17
of 56) of HM and SM patients respectively had
Table 1. Baseline characteristics of all patients.
Covariate Haematological malignancy Solid malignancy Total p-value
Total 52 127 179
Sex F 16 (31%) 58 (46%) 74 (41%)
M 36 (69%) 69 (54%) 105 (59%) 0.095
Age Median (IQR) 71 (60.75, 76) 73 (61.5, 82) 72 (61, 81) 0.075
Ethnicity White British 28 (54%) 47 (37%) 75 (42%) 0.28
Black 0 (0%) 6 (5%) 6 (3%)
South Asian 1 (2%) 2 (2%) 3 (2%)
West Asian 1 (2%) 2 (2%) 3 (2%)
Arab 1 (2%) 1 (1%) 2 (1%)
East Asian 0 (0%) 2 (2%) 2 (1%)
Latin American 0 (0%) 1 (1%) 1 (1%)
Unknown 21 (40%) 66 (52%) 87 (49%)
Index of multiple deprivation decile Median (IQR) 4 (1.75, 8) 3 (1, 5) 3 (1, 7) 0.039
Hypertension 15 (29%) 48 (38%) 63 (35%) 0.334
Hypercholesterolaemia 7 (13%) 22 (17%) 29 (16%) 0.284
Type II diabetes mellitus 10 (19%) 29 (23%) 39 (22%) 0.741
Dementia 1 (2%) 10 (8%) 11 (6%) 0.18
Cerebrovascular accident 1 (2%) 13 (10%) 14 (8%) 0.07
Chronic cardiac 16 (31%) 35 (28%) 51 (28%) 0.803
Chronic respiratory 11 (21%) 27 (21%) 38 (21%) 1
Chronic kidney disease 10 (19%) 22 (17%) 32 (18%) 0.93
Chronic liver 5 (10%) 6 (5%) 11 (6%) 0.371
Smoking Active 2 (4%) 14 (11%) 16 (9%)
Ex-smoker 25 (48%) 56 (44%) 81 (45%)
Never 20 (38%) 52 (41%) 72 (40%)
Unknown 5 (10%) 5 (4%) 10 (6%) 0.234
CANCER AND COVID-19 3
restarted treatment at the time of the last recorded
follow-up. Cancer treatment and the treatment intent
are summarized in Table 2 and Supplementary
Table 3.
Laboratory findings and viral load
More patients in the SM group had lymphopaenia
with a count <1 109/L (78% versus 59% in the HM
group, p¼ 0.003), however median counts were actu-
ally lower in HM (Supplementary Table 1). HM patients
had both more thrombocytopaenia (62% versus 23%
in SM, p< 0.001) and lower counts [116 109/L (IQR
80, 228) versus 220 109/L (IQR 159, 278) in SM,
p¼ 0.034]. Median hemoglobin was 105 g/dL (IQR 84,
128) in the HM group, compared with 117 g/dL (IQR
101, 132) in the SM group (p¼ 0.014). There was no
significant difference in viral load between HM and
SM groups (p¼ 0.092), or with illness severity or
outcome (p¼ 0.331, Supplementary Table 2), though
data were only available for 33% of cases (HM: 50%,
26 of 52 vs SM: 27%, 34 of 127).
Outcomes
Overall 66 patients died (37%), 25 patients with HM
and 41 with SM, giving mortality rates of 48% and
32% respectively (p¼ 0.069). Variables with p< 0.25 in
univariable analysis, (Table 3) were considered as can-
didates for inclusion in a multivariable Cox regression
model and hazard ratios (HR) calculated. In this model,
the risk of death was higher in the HM compared with
SM group [HR 2.94 (95% CI, 1.59–5.59), p¼ 0.001,
Table 3, Figure 2(A)].
Next, we performed sub-group analysis to investi-
gate the potential impact of systemic anticancer treat-
ment on mortality. Forty-four percent (79 of 179) had
received systemic anticancer treatment (including
Table 2. Cancer specific information.
Haematological malignancy, n (%) Solid malignancy, n (%)
Time between Cancer diagnosis
and COVID-19
0–3months 12 (26%) 18 (16%)
3–6months 3 (6%) 9 (8%)
6–12months 2 (4%) 6 (5%)
12–60months 17 (36%) 36 (32%)





<4weeks 30 (58%) 49 (39%)
4weeks to 12months 2 (4%) 18 (14%)
12months 6 (11%) 12 (9%)
Surgical <4weeks 0 (0%) 3 (2%)
4weeks to 12months 0 (0%) 5 (4%)
12months 4 (8%) 27 (21%)
Radiotherapy <4weeks 0 (0%) 6 (5%)
4weeks to 12months 0 (0%) 2 (2%)
12months 2 (4%) 24 (19%)
Cancer subtypes, n (%)
Haematological malignancy (n¼ 52) Lymphoid neoplasms (n¼ 34, 65%) Lymphoma 14 (41%)
Multiple myeloma 10 (29%)
Chronic lymphocytic leukemia 10 (29%)
Myeloid neoplasms and acute leukaemias
(n¼ 17, 33%)




Acute lymphoblastic leukemia 2 (12%)
Posttransplant lymphoproliferative disorder
(n¼ 1, 2%)
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chemotherapy, immunotherapy, targeted and/or endo-
crine therapy) within 4weeks prior to COVID-19 diag-
nosis. Of these, 27 died (34%), compared with 39% in
those not receiving systemic therapy (p¼NS).
Although there was no overall effect of chemotherapy
on survival (Figure 2(C)), there was a marked differ-
ence seen between HM and SM patients, with HM
patients more than twice as likely to die (16 of 30,
53%) then those in the SM group [22% (11 of 49),
p¼ 0.01]. When only patients receiving systemic
chemotherapy after exclusion of other systemic anti-
cancer treatment were then analyzed, HM group had
an even higher mortality rate of 62% (13 of 21) versus
17% (6 of 36) in the SM group with the risk of death
also being much higher [HR 8.33 (95% CI, 2.56–25),
p< 0.001]. Two-week survival was 52% (95% CI,
35–79%) in the HM group versus 94% (95% CI,
87–100%) in the SM group (Figure 2(D)).
A large difference in 14-day survival was also seen
in those with nosocomial COVID-19 [53% (95% CI,
38–76%)] than those with non-nosocomial infection
[78% (95% CI, 72–85%)] (Figure 2(B)). Univariable ana-
lysis gave a HR comparing the two groups of 2.47
[(95% CI, 1.43–4.29), p¼ 0.001], although this did not
translate into significance in the multivariable model.
Of interest was that ex-smokers appeared to have
worse overall survival compared with patients who never
smoked and active smokers (Supplementary Figure 2(A)).
However, even though this effect was again seen in uni-
variable Cox proportional model for ex-smokers com-
pared with active smokers [HR 3.52 (95% CI, 1.09–11.36),
p¼ 0.035], it was not seen between ex-smokers and
nonsmokers (p¼ 0.386, Table 3).
Furthermore, in the multivariable model, every 1-
year increase in age [HR 1.04 (95% CI, 1.01–1.07),
p¼ 0.003] was also seen to be an independent factor
associated with increased risk of death. There was a
trend toward increasing CRP level being associated
with increased risk of death which did not reach statis-
tical significance [HR 1.34 (95% CI, 1.00–1.80),
p¼ 0.052, also see Supplementary Figure 2(B)].
Radiological imaging
Chest radiograph was performed in all but one asymp-
tomatic patient, and 13% (23 of 179) underwent
Figure 1. Proportions of nosocomial transmission, severity of illness and complications between HM and SM groups. (A) Pie chart
with breakdown of patients with nosocomial COVID-19 along with proportion of patients who subsequently died. (B) Bar graph
showing severity of illness in HM and SM groups. (C) Differences in complication rate between HM and SM groups, split by
‘medical complications’ and ‘radiological complications.’ CCF: congestive cardiac failure; VTE: venous thromboembolism; AKI: acute
kidney injury; ARDS: acute respiratory distress syndrome; B/L: bilateral; Uni: unilateral; GG: ground glass; AS: airspace.
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computerized tomography (CT) of the thorax. Bilateral
airspace consolidation was the commonest finding
with 51% (26 of 51) and 41% (52 of 127) reported in
HM and SM groups, respectively (Figure 1(C)).
Unilateral pleural effusion (11.5 vs 13.4% for HM and
SM) was seen more frequently than bilateral pleural
effusions (9.6 vs 7.1% for HM and SM). ARDS was seen
in 9.6 and 7.1% of HM and SM cases, with pneumo-
thorax being a rare finding.
Medical complications during COVID-19 admission
Medical complications during the COVID-19 admission
occurred in 28% (51 of 179) of all cancer patients. Acute
kidney injury was the commonest complication in cancer
patients occurring in 21% (37 of 179). For patients who
developed AKI compared with those who did not, the
HR was 2.26 (95% CI, 1.34–3.82, p¼ 0.002). Symptomatic
CCF and VTE occurred in 4.5% (8 of 179) and 4% (7 of
179) of cancer patients respectively with breakdown
shown between HM and SM in Figure 1(C).
Hospital stay and discharge
Fifty percent (26 of 52) of HM patients were dis-
charged compared to 68% (86 of 127) SM patients at
the time of last follow-up. The median hospital stay
for patients who were discharged was 8 (IQR 3, 14)
days whereas the median hospital stay for patients
who died was 9 (IQR 5.5, 16) days. When comparing
HM and SM groups, the median follow-up time, esti-
mated using the reverse Kaplan–Meier method was 42
(IQR 38, 46) and 45 (IQR 42, 46) days, respectively.
Discussion
Patients with cancer appear to have a higher infection
rate with SARS-CoV-2 than the general population
[12,14–18], and also higher mortality [6]. In our multi-
centre audit, the mortality rate was 37% amongst all
cancer patients. This compares with a 44% hospital
mortality overall in the ISARIC WHO CCP-UK study
[6,8] which is the key national characterization proto-
col for the SARS-CoV-2 pandemic within the UK. This
supports the notion that cancer patients with COVID-
19 have worse outcomes compared to those without
cancer [11–14,17,19–25], although this is not con-
firmed in all studies [26,27]. Here, we report a signifi-
cantly higher mortality rate for patients with
haematological malignancy (HM, 48%) than with solid
malignancy (SM, 32%), also seen in other studies
[11,23,28]. Other haematological case series report a
Table 3. Univariable and multivariable analysis of covariates grouped into demographics, cancer type and nosocomial infection,
anticancer treatment and investigations with death as an outcome.
Univariable modeling Multivariable modeling
Covariates n est (se) HR (95% CI) p-value est (se) HR (95% CI) p-value
Demographics
Sex (male vs female) 178 0.37 (0.26) 1.44 (0.868, 2.402) 0.157
Age (years) 178 0.03 (0.009) 1.03 (1.007, 1.045) 0.007 0.04 (0.014) 1.04 (1.014, 1.07) 0.003
Hypertension (yes vs no) 178 0.32 (0.251) 1.37 (0.839, 2.246) 0.208
Chronic kidney disease (yes vs no) 178 0.48 (0.295) 1.61 (0.905, 2.879) 0.105
Type II diabetes mellitus (yes vs no) 178 0.21 (0.284) 1.23 (0.704, 2.144) 0.469
Chronic cardiac (yes vs no) 178 0.4 (0.259) 1.49 (0.898, 2.474) 0.123
Chronic respiratory (yes vs no) 178 0.1 (0.31) 0.91 (0.495, 1.671) 0.759
Index of multiple deprivation decile 121 0.04 (0.045) 1.05 (0.958, 1.142) 0.315
Ex-smokers vs active smokers 178 1.26 (0.598) 3.52 (1.09, 11.364) 0.035
Ex-smokers vs nonsmokers 178 0.71 (0.817) 2.03 (0.41, 10.059) 0.386
Cancer type and nosocomial infection
Haematological vs solid malignancy 178 1.67 (0.257) 1.82 (1.101, 3.012) 0.02 1.09 (0.321) 2.94 (1.59, 5.59) 0.001
Nosocomial infection (definite or probable) 172 0.91 (0.281) 2.47 (1.427, 4.289) 0.001
Anticancer treatment
Systemic< 4weeks 178 0.16 (0.251) 0.85 (0.521, 1.393) 0.522
Surgical < 4weeks 178 0.55 (0.719) 1.74 (0.425, 7.117) 0.442
Radiotherapy< 4weeks 178 1.03 (1.008) 0.36 (0.05, 2.585) 0.309
Investigations
SARS-CoV-2 PCR (Cq value) 60 0.07 (0.038) 0.94 (0.869, 1.007) 0.077
Increasing hemoglobin (g/dL) 139 0.57 (0.614) 0.57 (0.171, 1.894) 0.357
Increasing white cell count ( 109/L) 139 0.01 (0.008) 1.01 (0.996, 1.026) 0.165
Increasing neutrophil count ( 109/L) 138 0.03 (0.027) 1.03 (0.977, 1.088) 0.27
Increasing lymphocyte count ( 109/L) 139 0.03 (0.226) 1.03 (0.663, 1.609) 0.885
Increasing platelet count ( 109/L) 139 0.36 (0.142) 0.7 (0.529, 0.923) 0.012 0.3 (0.146) 0.74 (0.554, 0.982) 0.037
Increasing C-reactive protein (mg/L) 131 0.34 (0.138) 1.41 (1.073, 1.846) 0.013 0.29 (0.15) 1.34 (0.998, 1.796) 0.052
Increasing sodium (mmol/L) 137 0.01 (0.034) 1.01 (0.94, 1.075) 0.878
Increasing potassium (mmol/L) 135 0.56 (0.29) 0.57 (0.323, 1.008) 0.053
Covariates which had a p-value <0.25 were included in the multivariable modeling.
p-values <0.05 are highlighted in bold.
6 T. BHOGAL ET AL.
high mortality in HM patients of 35.9% [25] and 33%
in a study focused on patients with chronic lympho-
cytic leukemia [24].
In our cohort, the overall nosocomial infection rate
was 16%. The outcome from nosocomial infection was
markedly worse than from community-acquired infec-
tion. Although this difference was not maintained in
multivariable analysis, this does not detract from the
importance of this result. The reason that nosocomial
infection does not remain significant in multivariable
analysis is simply that it is likely to be a marker for
patients who have a high degree of healthcare inter-
action, and either have significant co-morbidities,
advanced cancer, are immunocompromised from their
treatment, or combination of these factors. It is there-
fore likely that the patient population accounts for
this and not the location of SARS-CoV-2 acquisition.
This result indicates that the in-patient cancer popula-
tion is extremely vulnerable to the effects of COVID-
19, and underlines the need to avoid nosocomial
transmission to these patients at all costs.
Systemic treatments for cancer are heterogeneous,
ranging from endocrine therapy right through to high
dose chemotherapy. In our cohort, when HM and SM
patients were compared, marked differences were
seen. The administration of systemic therapy increased
the risk of death from COVID-19, whereas in SM
patients it appeared to be protective. Given the par-
ticular effects of chemotherapy a further comparison
was performed where an even greater difference in
mortality between HM and SM was seen (62 vs 17%,
p< 0.001). The worse outcomes observed in HM
patients are likely due to the fact they are severely
immunocompromised – the resultant effect of the
underlying haematological malignancy and systemic
chemotherapy. It is however unclear why outcome
improves in the counterpart group of SM patients
receiving chemotherapy. Possibilities include: i) greater
marrow reserve, ii) differences in the use of granulo-
cyte colony-stimulating factors and iii) chemotherapy-
induced reduction in the neutrophil to lymphocyte
ratio, leading to improved outcomes, as previously
suggested [19].
While a number of studies have reported no impact
of chemotherapy on outcome [21,22,28], there are
others who have reported otherwise. For example,
Figure 2. Overall survival of (A) HM and SM patients; (B) nosocomial COVID-19 transmission (definite or probable) and non-noso-
comial infection (community acquired or indeterminate cases); (C) all cancer patients receiving systemic anticancer treatment
within 4weeks of COVID-19 and those who did not and (D) HM and SM patients who received chemotherapy within 4weeks of
COVID-19.
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Zhang et al. [13] reported that anticancer treatment
within 14 days of COVID-19 increased the risk of
severe events. Similarly, Lee et al. showed that
patients with HM receiving recent chemotherapy had
worse outcomes, supporting the findings of our study
[28,29]. Chemotherapy appeared to be protective in
patients with solid organ malignancies, however, per-
haps because this delineates a group of patients who
are fitter than average, by virtue of being fit enough
to receive chemotherapy. Finally, it must be acknowl-
edged that the difference in the absolute number of
deaths between these groups in this cohort is small,
so these findings may be due to chance alone.
Interestingly, ex-smokers appeared to have an
improved survival compared to nonsmokers as sug-
gested in previous reports [21,30]. The reasons for this
remain unclear and require further detailed explor-
ation. One possibility is that COPD predominantly
affects smokers so these patients receive steroids,
which are now known to improve outcome in COVID-
19 [31].
Various limitations exist in our study. Firstly,
although this is one of the largest cancer cohorts
reported with COVID-19, the numbers remain small to
infer definite conclusions and therefore larger studies
will be required to confirm our findings. Secondly, the
retrospective design of the study limited the quality of
data collected. Thirdly, an attempt was made to stand-
ardize definitions used, however, due to variation in
practices across England, complications may have
been coded differently in various hospitals. Fourthly,
data were incomplete in some cases, further affecting
the interpretability of results. Due to the small num-
bers, subgroup analysis was limited. Since there is no
real-time capture of data, current studies are affected
by issues of selection and recall bias. Furthermore,
absence of non-cancer controls prevents stratification
of patients which is important to adjust for unmeas-
ured confounders.
We have observed that appreciable mortality exists
in this cohort of UK cancer patients hospitalized with
COVID-19. Patients with haematological malignancies
are at the highest risk of death within this group,
either because of the immunosuppressive effects of
cytotoxic chemotherapy, their underlying disease or
both. Nosocomial infection carries a high mortality,
especially in those who have HM and have received
chemotherapy recently (Figure 3) not because of
where infection takes place, but most likely because
the patients who acquire infection in hospital repre-
sent a particularly vulnerable group. Preventing in-hos-
pital transmission to highly vulnerable patients should
be a priority for care providers going forward into the
first full winter season since the emergence of COVID-
19 in the UK. Potential measures include ‘clean’ sites
where cancer patients can be admitted away from
patients being cared for with COVID-19, the use of
dedicated teams for the most vulnerable patients,
regular testing of staff, and strict adherence to hos-
pital infection control measures. Further work is now
Figure 3. Risk of death relating to nosocomial infection, type of malignancy and whether chemotherapy was received within
4weeks of COVID-19. The color codes signify the risk of death. HM: haematological malignancy; SM: solid malignancy. HM and SM
groups refer to all patients who did not receive chemotherapy within 28 days of COVID-19.
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underway to understand the impact of COVID-19 in
cancer patients in the UK when controlled for key fac-
tors including age and ethnicity.
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